Human CHO-K1/MTLR/Gα15 Stable Cell Line

[CAT#: NCL20120091CR]

Motilin Receptor Stable Cell Line

Species:: Human

Applications:: GPCR Screening

Cell Types:: Other Cells

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Request Pricing

Inquiry

Product Overview

Description

The motilin receptor (MTLR) represents a clinically useful pharmacological target, as agonists binding to the MTLR have gastroprokinetic properties. Motilin is a 22 amino acid peptide that potently stimulates gastrointestinal contractility. The biological effects of motilin are mediated by a Gq-coupled seven transmembrane protein, currently termed motilin receptor (MR) that shares significant sequence similarity with the ghrelin receptor. The motilin receptor is also activated by the antibiotic erythromycin; this interaction appears to mediate some of the gastrointestinal side effects of erythromycin.

Cell Types

Other Cells

Applications

GPCR Screening

Research Areas

GPCR

Species

Human

Properties

Size

>1x10^6 Cells

Form

Frozen cells

Culture Medium

Ham's F12, 10% FBS, 400 μg/ml G418, 100 μg/ml Hygromycin B

Freeze Medium

45% culture medium, 45% FBS, 10% DMSO

Receptor

MTLR/MLNR

Family

Motilin receptor

Strain

MTLR/Gα15 Cell Line

Cell Purity

>95%

Shipping

Dry ice

Storage

Liquid nitrogen immediately upon delivery

Handling Advice

Avoid inhalation. Avoid contact with eyes, skin, and clothing. Avoid prolonged or
repeated exposure.

Research Use Only

For research use only, not for diagnostic or therapeutic use.

Warnings

Store under recommended storage conditions (liquid nitrogen). Do not expose to high temperature. After expiration, discard all remaining reagents.

Target Details

Target

MTLR

Official Name

MTLR

Alternative Names

motilin receptor; MTLR; MOT-R; MTLR1; GPR38; G protein-coupled receptor 38

Gene ID

2862(Human); 675957(Mouse)

Uniprot ID

O43193(Human)

References

1. Cui, J., Wang, H., Medina, R., Zhang, Q., Xu, C., Indig, I. H.,.. & Guo, L. (2020). Inhibition of PP2A with LB-100 enhances efficacy of CAR-T cell therapy against glioblastoma. Cancers, 12(1), 139. 2. Matvienko, D. A., Kulemzin, S. V., Smagina, A. S., Belovezhets, T. N., Chikaev, A. N., Volkova, O. Y.,.. & Gorchakov, A. A. (2018). Analysis of in vitro activity of PSCA-specific CARs in the context of human NK cell line YT. Cell Ther. Transplant., 7, 70-76. 3.

Publications